<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zapevalova MV</submitter><funding>Ministry of Science and Higher Education of the Russian Federation</funding><funding>the Ministry of Science and Higher Education of the Russian Federation</funding><pagination>10854</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9503112</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(18)</volume><pubmed_abstract>A (series) range of potential dimorpholinoquinazoline-based inhibitors of the &lt;i>PI3K/Akt/mTOR cascade&lt;/i> was synthesized. Several compounds exhibited cytotoxicity towards a panel of cancer cell lines in the low and sub-micromolar range. Compound &lt;b>7c&lt;/b> with the highest activity and moderate selectivity towards MCF7 cells which express the mutant type of PI3K was also tested for the ability to inhibit PI3K-(signaling pathway) downstream effectors and associated proteins. Compound &lt;b>7c&lt;/b> inhibited the phosphorylation of Akt, mTOR, and S6K at 125-250 nM. It also triggered PARP1 cleavage, ROS production, and cell death via several mechanisms. Inhibition of PI3Kα was observed at a concentration of &lt;b>7b&lt;/b> 50 µM and of &lt;b>7c&lt;/b> 500 µM and higher, that can indicate minority PI3Kα as a </pubmed_abstract><journal>International journal of molecular sciences</journal><pubmed_title>Synthesis, Molecular Docking, In Vitro and In Vivo Studies of Novel Dimorpholinoquinazoline-Based Potential Inhibitors of PI3K/Akt/mTOR Pathway.</pubmed_title><pmcid>PMC9503112</pmcid><funding_grant_id>13.1902.21.0004</funding_grant_id><pubmed_authors>Maleev AA</pubmed_authors><pubmed_authors>Fonareva IP</pubmed_authors><pubmed_authors>Svirshchevskaya EV</pubmed_authors><pubmed_authors>Kuimov AN</pubmed_authors><pubmed_authors>Zapevalova MV</pubmed_authors><pubmed_authors>Shchegravina ES</pubmed_authors><pubmed_authors>Fedorov AY</pubmed_authors><pubmed_authors>Salnikova DI</pubmed_authors><pubmed_authors>Ignatov SK</pubmed_authors><pubmed_authors>Grishin ID</pubmed_authors><pubmed_authors>Konovalova MV</pubmed_authors><pubmed_authors>Scherbakov AM</pubmed_authors><pubmed_authors>Sorokin DV</pubmed_authors></additional><is_claimable>false</is_claimable><name>Synthesis, Molecular Docking, In Vitro and In Vivo Studies of Novel Dimorpholinoquinazoline-Based Potential Inhibitors of PI3K/Akt/mTOR Pathway.</name><description>A (series) range of potential dimorpholinoquinazoline-based inhibitors of the &lt;i>PI3K/Akt/mTOR cascade&lt;/i> was synthesized. Several compounds exhibited cytotoxicity towards a panel of cancer cell lines in the low and sub-micromolar range. Compound &lt;b>7c&lt;/b> with the highest activity and moderate selectivity towards MCF7 cells which express the mutant type of PI3K was also tested for the ability to inhibit PI3K-(signaling pathway) downstream effectors and associated proteins. Compound &lt;b>7c&lt;/b> inhibited the phosphorylation of Akt, mTOR, and S6K at 125-250 nM. It also triggered PARP1 cleavage, ROS production, and cell death via several mechanisms. Inhibition of PI3Kα was observed at a concentration of &lt;b>7b&lt;/b> 50 µM and of &lt;b>7c&lt;/b> 500 µM and higher, that can indicate minority PI3Kα as a </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2026-04-08T11:48:57.929Z</modification><creation>2025-02-19T00:44:29.375Z</creation></dates><accession>S-EPMC9503112</accession><cross_references><pubmed>36142768</pubmed><doi>10.3390/ijms231810854</doi></cross_references></HashMap>